Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast Features at Upcoming U.S. Investor Conferences

NEW YORK and MELBOURNE, Australia, March 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it will be featured at two investor conferences in March: ...
February 20, 2019 17:16 ET | Source: Mesoblast Limited

Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018

MELBOURNE, Australia and NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its financial results and operational highlights for the six months ended...
February 19, 2019 06:00 ET | Source: Mesoblast Limited

Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure

NEW YORK and MELBOURNE, Australia, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in development and commercialization of cellular medicines, announced...
February 13, 2019 17:06 ET | Source: Mesoblast Limited

Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018

NEW YORK and MELBOURNE, Australia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the half year and second quarter ended December 31,...
January 14, 2019 10:46 ET | Source: Mesoblast Limited

Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs

NEW YORK and MELBOURNE, Australia, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it has drawn down a further US$15 million from its US$75 million,...
January 07, 2019 19:44 ET | Source: Mesoblast Limited

Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco

NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), world leader in the development and commercialization of cellular medicines, today...
January 07, 2019 06:00 ET | Source: Mesoblast Limited

Phase 3 Trial of Mesoblast’s Cell Therapy in Chronic Heart Failure Completes Recruitment

NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), world leader in development and commercialization of allogeneic (off-the-shelf)...
December 28, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast Corporate Review

NEW YORK and MELBOURNE, Australia, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine...
December 24, 2018 06:30 ET | Source: Mesoblast Limited

Mesoblast to Present at 2019 Biotech Showcase in San Francisco

NEW YORK and MELBOURNE, Australia, Dec. 24, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) will report on its Phase 3 trials and commercial plans at the upcoming Biotech Showcase...
December 19, 2018 07:22 ET | Source: Mesoblast Limited

Mesoblast Makes Executive Appointment to Drive Product Commercialization

NEW YORK and MELBOURNE, Australia, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that it has appointed Eric Strati, PhD, to the new position of Senior...